A novel MMP-9 inhibitor exhibits selective inhibition in non-small-cell lung cancer harboring EGFR T790M mutation by blocking EGFR/STAT3 signaling pathway
- 21 March 2025
- journal article
- Published by Elsevier in Bioorganic Chemistry
- Vol. 159, 108393
Abstract
No abstract availableKeywords
Funding Information
- Guangxi Natural Science Foundation (2024GXNSFBA010100, 2024GXNSFAA010190, 2024GXNSFFA010015)
- National Natural Science Foundation of China (82460715)
This publication has 46 references indexed in Scilit:
- Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR MutationsJournal of Thoracic Oncology, 2021
- Resveratrol sensitizes lung cancer cell to TRAIL by p53 independent and suppression of Akt/NF-κB signalingLife Sciences, 2018
- Epidermal growth factor receptor-mediated regulation of matrix metalloproteinase-2 and matrix metalloproteinase-9 in MCF-7 breast cancer cellsMolecular and Cellular Biochemistry, 2018
- CD74-ROS1 G2032R mutation transcriptionally up-regulates Twist1 in non-small cell lung cancer cells leading to increased migration, invasion, and resistance to crizotinibCancer Letters, 2018
- Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLCLung Cancer, 2017
- Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patientsNature Communications, 2016
- Ginkgolic Acid Inhibits Invasion and Migration and TGF‐β‐Induced EMT of Lung Cancer Cells Through PI3K/Akt/mTOR InactivationJournal of Cellular Physiology, 2016
- Osimertinib: First Global ApprovalDrugs, 2016
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- MMP‐9 controls Schwann cell proliferation and phenotypic remodeling via IGF‐1 and ErbB receptor‐mediated activation of MEK/ERK pathwayGlia, 2009